Related Experiment Videos
Solitary mastocytoma treated with tranilast
1Department of Dermatology, Kyoto Prefectural University of Medicine, Japan.
Insights
Tranilast, a mast cell stabilizer, effectively treated solitary mastocytoma in infants, leading to nodule resolution and no relapses. This compound may inhibit mast cell degranulation and reduce mast cell numbers.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Solitary mastocytoma is a rare skin condition in infants.
- Mast cell stabilizers offer a potential therapeutic approach.
Abstract:
Two infants with solitary mastocytoma were treated with 5 mg/kg/day of tranilast [N-(3',4'-dimethoxycinnamoyl)anthranilic acid], a mast cell stabilizing compound extracted from Nandina domestica. Tranilast was administered orally in three divided doses. In one infant, a topical corticosteroid was also applied in combination with the oral tranilast. Patients experienced symptomatic relief, and nodules resolved almost completely after eight weeks of treatment. Tranilast therapy was continued for six months. No relapses were observed after discontinuation of therapy. We speculated that tranilast not only inhibited mast cell degranulation but also reduced the number of mast cells.